[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells
Affiliations: Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan, Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
- Published online on: November 25, 2015 https://doi.org/10.3892/ijo.2015.3265
- Pages: 854-854
Copyright: © Fujiwara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.